x NoneEntity Type
0001536196
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Can-Fite BioPharma Ltd.
Jurisdiction of Incorporation/OrganizationISRAEL 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Can-Fite BioPharma Ltd. 
Street Address 1Street Address 2
 10 BAREKET STREET, KIRYAT MATALON 
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 PETACH TIKVA ISRAEL 4951778 972 39241114 



3. Related Persons
Last NameFirst NameMiddle Name
CohnIlan
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
FishmanPnina
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
BornsteinYossi
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
FarbsteinMotti
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
 

 
Last NameFirst NameMiddle Name
RegevGuy
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
SartaniAbraham
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

Last NameFirst NameMiddle Name
GoldmanYaacov
Street Address 1Street Address 2
10 Bareket Street, Kiryat MatalonPO Box 7537
CityState/Province/CountryZIP/Postal Code
Petach TikvaISRAEL4951778
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  x Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2021-12-20 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
x Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
 H.C. Wainwright & Co., LLC 375
(Associated) Broker or Dealer x None(Associated) Broker or Dealer CRD Number x None
    
Street Address 1Street Address 2
 430 PARK AVENUE 4TH FLOOR
City State/Province/CountryZIP/Postal Code
 NEW YORK NEW YORK 10022
State(s) of Solicitation o All States o Foreign/Non-US
 NEW YORK
 

 



13. Offering and Sales Amounts
Total Offering Amount $ 10000000 USD o Indefinite
Total Amount Sold $ 10000000 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
 The warrants and shares underlying the warrants, the subject matter of this Form D, were issued in connection with the immediate exercise of certain warrants to purchase up to an aggregate of 150,000,000 ordinary shares represented by 5,000,000 ADSs.


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 1


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 700000 USD o Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
 H.C. Wainwright is also entitled to non-accountable expense reimbursement of $75,000 and warrants to purchase an aggregate of 350,000 ADSs exercisable at $2.00 per ADS for five years.


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Can Fite BioPharma (AMEX:CANF)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Can Fite BioPharma.
Can Fite BioPharma (AMEX:CANF)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Can Fite BioPharma.

Noticias sobre Can-fite Biopharma Ltd. CANF

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Jueves 25 de Abril 2024 (21 horas hace) • Business Wire
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Lunes 15 de Abril 2024 (2 semanas hace) • Business Wire
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Miércoles 3 de Abril 2024 (3 semanas hace) • Business Wire
Can-Fite Reports 2023 Financial Results and Clinical Update
Jueves 28 de Marzo 2024 (4 semanas hace) • Business Wire
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lunes 11 de Marzo 2024 (2 meses hace) • Edgar (US Regulatory)
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Lunes 11 de Marzo 2024 (2 meses hace) • Business Wire
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Miércoles 28 de Febrero 2024 (2 meses hace) • Edgar (US Regulatory)
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
Miércoles 28 de Febrero 2024 (2 meses hace) • Business Wire
Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Miércoles 14 de Febrero 2024 (2 meses hace) • Edgar (US Regulatory)
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Martes 30 de Enero 2024 (3 meses hace) • Edgar (US Regulatory)
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Martes 30 de Enero 2024 (3 meses hace) • Business Wire
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lunes 29 de Enero 2024 (3 meses hace) • Edgar (US Regulatory)

Más de Can-fite Biopharma Ltd. Artículos de Noticias